Literature DB >> 24960628

Factors affecting the outcome of related allogeneic hematopoietic cell transplantation in patients with Fanconi Anemia.

Mouhab Ayas1, Khawar Siddiqui2, Abdullah Al-Jefri2, Hassan El-Solh2, Ali Al-Ahmari2, Ashraf Khairy2, Samer Markiz2, Hasan Shahin2, Abdulrahman Al-Musa2, Amal Al-Seraihy2.   

Abstract

Hematopoietic cell transplantation (HCT) can cure bone marrow failure in patients with Fanconi Anemia (FA), and it is generally accepted that these patients should receive low-intensity conditioning because of the underlying DNA repair defect in their cells. Outcomes for recipients of matched related HCT have generally been favorable, but only a few studies have scrutinized the factors that may affect the eventual outcome of these patients. This retrospective analysis of 94 pediatric patients with FA who underwent related HCT at King Faisal Specialist Hospital & Research Center was carried out to attempt to identify factors that may affect outcome. Results showed overall survival (OS) probabilities of 92.5%, 89%, and 86% at 1, 5, and 10 years, respectively. In univariate analysis, use of higher dose cyclophosphamide (CY) (60 mg/kg) conditioning was associated with a better 10-year OS than lower dose CY (20 mg/kg) conditioning (91% versus 82%, respectively; P = .035), and use of radiation-containing regimens was associated with a significantly lower 10-year OS than nonradiation regimens (76% versus 91%, respectively; P = .005). Of the 4 regimens used in this study, the fludarabine-based regimen was associated with the highest survival (95.2%; P = .034). The use of the higher dose CY (60 mg/kg) was associated with a significantly increased incidence of hemorrhagic cystitis (HC) (20% versus 5.6% respectively; P = .049). Three patients (3%) developed squamous cell carcinoma (2 oropharyngeal and 1 genitourinary), at 9.4, 5.4, and 13.3 years after HCT; 2 of them had radiation-containing conditioning. In conclusion, our data suggest that although using a higher dose CY (60 mg/kg) conditioning regimen may be associated with better survival, it is also associated with a significantly increased risk of HC. The addition of fludarabine to the low-dose CY (20 mg/kg) is associated with the best survival. On the other hand, radiation-containing regimens are associated with significantly lower survival.
Copyright © 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cyclophosphamide; Fanconi anemia; Radiation; Stem cell transplantation

Mesh:

Substances:

Year:  2014        PMID: 24960628     DOI: 10.1016/j.bbmt.2014.06.016

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  4 in total

1.  Preemptive Bone Marrow Transplantation for FANCD1/BRCA2.

Authors:  Nicholas E Khan; Philip S Rosenberg; Harold P Lehmann; Blanche P Alter
Journal:  Biol Blood Marrow Transplant       Date:  2015-07-14       Impact factor: 5.742

2.  Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure.

Authors:  Mouhab Ayas; Mary Eapen; Jennifer Le-Rademacher; Jeanette Carreras; Hisham Abdel-Azim; Blanche P Alter; Paolo Anderlini; Minoo Battiwalla; Marc Bierings; David K Buchbinder; Carmem Bonfim; Bruce M Camitta; Anders L Fasth; Robert Peter Gale; Michelle A Lee; Troy C Lund; Kasiani C Myers; Richard F Olsson; Kristin M Page; Tim D Prestidge; Mohamed Radhi; Ami J Shah; Kirk R Schultz; Baldeep Wirk; John E Wagner; H Joachim Deeg
Journal:  Biol Blood Marrow Transplant       Date:  2015-06-23       Impact factor: 5.742

3.  Hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: risk factors, graft source and survival.

Authors:  L E Lunde; S Dasaraju; Q Cao; C S Cohn; M Reding; N Bejanyan; B Trottier; J Rogosheske; C Brunstein; E Warlick; J A H Young; D J Weisdorf; C Ustun
Journal:  Bone Marrow Transplant       Date:  2015-07-13       Impact factor: 5.483

4.  Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Fanconi Anemia.

Authors:  Hosein Kamranzadeh Fumani; Mohammad Zokaasadi; Amir Kasaeian; Kamran Alimoghaddam; Asadollah Mousavi; Babak Bahar; Mohammad Vaezi; Ardeshir Ghavamzadeh
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-11-01       Impact factor: 2.576

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.